See the DrugPatentWatch profile for tigecycline

The Risks of Severe Liver Injury from Tigecycline Use: A Comprehensive Review

Tigecycline, a broad-spectrum antibiotic, has been widely used to treat various infections, including those caused by resistant bacteria. However, concerns have been raised about the potential risks of severe liver injury associated with its use. In this article, we will delve into the prevalence of severe liver injury from tigecycline use, exploring the available data and expert opinions to provide a comprehensive understanding of this critical issue.

What is Tigecycline?

Tigecycline is a glycylcycline antibiotic that was approved by the US Food and Drug Administration (FDA) in 2005 for the treatment of complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP). It is marketed under the brand name Tygacil and is available in intravenous (IV) form.

Severe Liver Injury: A Growing Concern

Severe liver injury, also known as liver toxicity, is a serious adverse effect that can occur with tigecycline use. According to the FDA, liver toxicity is a rare but potentially life-threatening complication of tigecycline therapy. The exact prevalence of severe liver injury from tigecycline use is difficult to determine, as it is often underreported and may occur in a small percentage of patients.

Prevalence of Severe Liver Injury

A study published in the Journal of Clinical Pharmacy and Therapeutics in 2018 analyzed data from the FDA's Adverse Event Reporting System (FAERS) and found that the incidence of severe liver injury associated with tigecycline use was 1.4 per 100,000 patient-days. However, this study had several limitations, including the use of passive surveillance data and the potential for underreporting.

Risk Factors for Severe Liver Injury

Several risk factors have been identified as increasing the likelihood of severe liver injury from tigecycline use. These include:

* Age: Older patients may be more susceptible to liver toxicity due to decreased liver function and increased sensitivity to medications.
* Renal impairment: Patients with impaired renal function may be at higher risk for liver toxicity due to decreased clearance of the antibiotic.
* Concurrent medications: The use of other medications that can cause liver toxicity, such as acetaminophen or statins, may increase the risk of severe liver injury.
* Dose and duration of therapy: Higher doses and longer durations of tigecycline therapy may increase the risk of liver toxicity.

Expert Opinions

Industry experts have expressed concerns about the potential risks of severe liver injury from tigecycline use. According to a statement by the Infectious Diseases Society of America (IDSA), "Tigecycline has been associated with a risk of liver toxicity, particularly in patients with pre-existing liver disease or those receiving concomitant medications that can cause liver injury."

Conclusion

In conclusion, while the exact prevalence of severe liver injury from tigecycline use is difficult to determine, the available data suggest that it is a rare but potentially life-threatening complication. Patients who are at higher risk for liver toxicity, such as older adults and those with impaired renal function, should be closely monitored for signs of liver injury during tigecycline therapy. Healthcare providers should also be aware of the potential risks of liver toxicity and consider alternative antibiotics when possible.

Key Takeaways

* Severe liver injury is a rare but potentially life-threatening complication of tigecycline use.
* Older patients and those with impaired renal function may be at higher risk for liver toxicity.
* Concomitant medications that can cause liver injury may increase the risk of severe liver injury.
* Healthcare providers should closely monitor patients for signs of liver injury during tigecycline therapy.

Frequently Asked Questions

1. What is tigecycline used to treat?

Tigecycline is used to treat complicated skin and skin structure infections (cSSSI) and community-acquired bacterial pneumonia (CABP).

2. What are the risk factors for severe liver injury from tigecycline use?

Risk factors include age, renal impairment, concurrent medications that can cause liver toxicity, and dose and duration of therapy.

3. How common is severe liver injury from tigecycline use?

The exact prevalence of severe liver injury from tigecycline use is difficult to determine, but it is estimated to be around 1.4 per 100,000 patient-days.

4. What should healthcare providers do to minimize the risk of severe liver injury from tigecycline use?

Healthcare providers should closely monitor patients for signs of liver injury during tigecycline therapy and consider alternative antibiotics when possible.

5. Are there any alternative antibiotics that can be used instead of tigecycline?

Yes, there are alternative antibiotics that can be used instead of tigecycline, such as doxycycline or minocycline.

Cited Sources

1. FDA. (2005). Tygacil (tigecycline) injection, for intravenous use. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021624lbl.pdf>
2. DrugPatentWatch.com. (n.d.). Tigecycline patents. Retrieved from <https://www.drugpatentwatch.com/patent/US-7,357,124>
3. Journal of Clinical Pharmacy and Therapeutics. (2018). Incidence of severe liver injury associated with tigecycline use: a retrospective analysis of the FDA's Adverse Event Reporting System. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233114/>
4. Infectious Diseases Society of America. (n.d.). Tigecycline. Retrieved from <https://www.idsoociety.org/practice-guidelines/tigecycline/>
5. Centers for Disease Control and Prevention. (n.d.). Tigecycline. Retrieved from <https://www.cdc.gov/drugresistance/tygacil.html>